TokenPost·
Biogen Raises 2026 EPS Guidance Floor as Growth Portfolio Expands
The Growth Portfolio generated $1.26 billion, up 49% year over year, while multiple sclerosis product revenue fell 13% to $919 million.
More news
- TokenPostUrban Edge Raises 2026 Guidance After Revenue Tops Estimates
- TokenPostBinance’s BABAUSDT Perpetual Futures Contract Was Quoted at $100.99 on Oct. 28
- TokenPostSouth Korean Regulators Begin Bithumb Inspections After Breach Report
- TokenPostOld Dominion Freight Line Beats Q3 EPS Estimates With $1.59B Revenue
- Bitcoin MagazineBitcoin Price “Climbing the Wall of Worry” – Early Signs of Bull Market | Michael Sullivan
- TokenPostAmarin Reports $39.6 Million in Revenue for Third Quarter of 2026